Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Epilepsy

No studies found 0 · 0%GRADE not reported 1 · 33.3%Very low 0 · 0%Low 1 · 33.3%Moderate 0 · 0%High 1 · 33.3%

All adverse effects · participants with epilepsy (GTCS)

Sulthiame showed no clear difference in all adverse effects compared with phenytoin (low certainty).

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
RR 1.05 [0.54, 2.07]
1 study · 146 participants
Low

All adverse effects · people with epilepsy

1 finding from 1 review

Sulthiame monotherapy for epilepsy 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 100 participants
GRADE not reported

Adverse effects ‐ 'thinking abnormally' · people with drug‐resistant focal epilepsy

Topiramate leads to higher adverse effects ‐ 'thinking abnormally' compared with placebo (high certainty).

1 finding from 1 review

Topiramate add‐on therapy for drug‐resistant focal epilepsy 2019 · Cochrane Headline outcomes only
RR 5.7 [2.26, 14.38]
4 studies · 640 participants
High